Cargando…
Rimonabant, Gastrointestinal Motility and Obesity
BACKGROUND: Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated ri...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Science Publishers
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468875/ https://www.ncbi.nlm.nih.gov/pubmed/23449551 http://dx.doi.org/10.2174/157015912803217297 |